TEVA — TEVA PHARMA INDUSTRIES LTD ADR (Healthcare >> Drug Manufacturers - Specialty & Generic)
TEVA FAQ
What is TEVA's P/E ratio?
TEVA PHARMA INDUSTRIES LTD ADR (TEVA) currently trades at a P/E ratio of 25.72.
What is TEVA's ROE?
TEVA PHARMA INDUSTRIES LTD ADR reports a Return on Equity (ROE) of 19.01%.
What is TEVA's dividend yield?
TEVA PHARMA INDUSTRIES LTD ADR offers a dividend yield of 0.00%.
What is TEVA's Deepscope Quality Score?
Deepscope rates TEVA's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TEVA?
Deepscope's AI Timing Score for TEVA is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TEVA belong to?
TEVA PHARMA INDUSTRIES LTD ADR is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NYSE exchange.
|
USD 34.19
Price
-0.24
(-0.70%)
Day Change
|
|
|---|
TEVA, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
2208
|
| Magic Formula Rank by ROE |
2208
|
| Magic Formula Rank by ROIC |
2256
|
| Price | 34.19 |
| PBV / Sector |
4.89 / 2.76
|
| Earning Per Share | 1.33 |
| PE / Sector |
25.72 / 23.64
|
| PEG or PE/Growth / Sector |
-1.10 / 0.13
|
| Average 1M Daily Value |
162.96 M
GREAT
|
| Average 1W Daily Value |
199.39 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:11 |
| Symbol | TEVA |
| Name | TEVA PHARMA INDUSTRIES LTD ADR |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NYSE |
| Listed Shares | 1,164.43 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 40,230.95 / 9,835.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 124 Dvora HaNevi?a St., Tel Aviv-Yafo, Israel, 6944020
Phone: 972 3 914 8213
Website: https://www.tevapharm.com
Employees: 31,173
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google